Amphastar Pharmaceuticals (AMPH) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amphastar Pharmaceuticals (AMPH) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 8.6% versus a loss of 67.4%. Mineralys Therapeutics is the larger company by market cap ($1.21 billion vs $1.20 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | MLYS |
|---|---|---|
| Share price | $28.25 | $13.66 |
| Market cap | $1.20B | $1.21B |
| 1-day change | +0.50% | -3.53% |
| YTD return | +5.49% | -62.36% |
| 1-year return | +8.61% | -67.38% |
| 5-year return | +41.89% | — |
| P/E ratio (TTM) | 12.96 | — |
| Forward P/E | 8.43 | — |
| EPS (TTM) | $2.18 | $-4.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $719.89M | — |
| Revenue growth (YoY) | -1.65% | — |
| Net income (latest FY) | $98.09M | $-154.65M |
| Gross margin | 49.46% | — |
| Operating margin | 19.50% | — |
| Net margin | 13.63% | — |
| 52-week high | $31.00 | $44.13 |
| 52-week low | $16.65 | $13.57 |
| Distance from 52-week high | -8.87% | -69.05% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -13.27% | +218.89% |
| Average volume | 475.35K | 1.55M |
| Shares outstanding | 42.65M | 88.56M |
| Employees | 1,976 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMPH has outperformed MLYS by 76.0 percentage points over the past year.
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
AMPH vs MLYS FAQ
Which is bigger, Amphastar Pharmaceuticals or Mineralys Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.21B compared with $1.20B for Amphastar Pharmaceuticals (AMPH).
Which stock has performed better over the past year, AMPH or MLYS?
AMPH returned +8.61% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Amphastar Pharmaceuticals and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.